Table 1.

NF-κB–Deficient Primary MEFs Remain Viable after Doxorubicin Treatment

Viabilitywtc-rel−/−rela−/−nfkb1−/−rela−/−c-rel−/−rela−/−p53−/−
Medium78.7 ± 1.378.4 ± 1.676.2 ± 0.975.8 ± 0.878.4 ± 1.779 ± 0.7
200 ng/mL doxorubicin74.6 ± 3.272.8 ± 071.9 ± 1.574 ± 1.674.5 ± 0.676.8 ± 1.7
  • NOTE: wt, NF-κB–deficient, and p53-deficient MEFs were exposed to 200 ng/mL doxorubicin for 24 h. Floating and adherent cells were combined and stained with FITC-conjugated Annexin V, and the percentage of viable cells was determined by fluorescence-activated cell sorting. The values represent the mean ± SD of duplicates from two independent experiments.